#
##
##
|**Trustees**|Professor A N Barclay, DPhil|
|---|---|
||Professor J Errington, FRS, FMedSci|
||Professor Sir John Walker, FRS, FMedSci|
||Professor Penny Handford, Dphil|
||ProfessorARGreen, PhD|
||Professor Anton van der Merwe|
|**Charity number**|309698|
|**Auditor**|Critchleys Audit LLP|
||Beaver House|
||23-38 Hythe Bridge Street|
||Oxford|
||OX12EP|
|**Bankers**|CAF BankLtd|
||25 King Hill Avenue|
||West Malling|
||Kent|
||ME19 4JQ|
|**Solicitors**|Knights Solicitors|
||Midland House|
||West Way|
||Oxford|
||OX20PH|
|**Investment advisors**|Schroder (Cazenave) Personal Investment Management|
||1 London Wall Place|
||London|
||EC2Y 5AU|
||OU Endowment Management|
||27Park End Street|
||Oxford|
||OX11HU|
||BMO Global Asset Management|
||12 Primrose St|
||Exchange House|
||London|
||EC2A2NY|
##
##
||**Page**|
|---|---|
|Trustees report|1 - 3|
|StatementofTrustees responsibilities|4|
|Independent auditor's report|5-8|
|Statementoffinancial activities|9 - 10|
|Balance sheet|11|
|Statementofcash flows|12|
|Notestothe financial statements|13-**24**|
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
24/10/2022
##
##
|**Current financial year**||||||
|---|---|---|---|---|---|
|||**Unrestricted**|**Endowment**|
**Total**|Total|
|||**funds**|**funds**|||
|||**2022**|**2022**|**2022**|2021|
||**Notes**|£|£|£|
£|
|**Income from:**||||||
|Investment Income|3|3,841,435||3,841,435|3,527,725|
|**Expenditure on:**||||||
|Investment Management Costs|**4**|2,149|-|2,149|1,702|
|Charitable activities||||||
|Administrative costs|**5**|22,401|-|22,401|16,878|
|Grants Awarded|**5**|1,880,504||1,880,504|861,920|
|**Total charitable expenditure**||1,902,905||1,902,905|878,798|
|**Total resources expended**||1,905,054|-|1,905,054|880,500|
|Net gains/(losses) on investments|**9**|-|3,438,038|3,438,038|20,226,663|
|**Net incoming resources before transfers**||1,936,381|3,438,038|5,374,419|22,873,888|
|Gross transfers between funds||(1,325,161)|
1,325,161|||
|Fund balances at 6 April 2021||1,327,949|98,759,051|100,087,000|77,213,112|
|**Fund balancesat5 April 2022**||1,939,169|103,522,250|105,461,419|100,087,000|
##
##
##
|**Prior financial year**|||||
|---|---|---|---|---|
|||**Unrestricted**|**Endowment**|**Total**|
|||**funds**|**funds**||
|||**2021**|**2021**|**2021**|
||**Notes**|£|£|£|
|**Income from:**|||||
|Investment Income|**3**|3,527,725||3,527,725|
|||-|||
|**Expenditure on:**|||||
|Investment Management Costs|**4**|1,702||1,702|
|Charitable activities|||||
|Administrative costs|**5**|16,878||16,878|
|Grants Awarded|**5**|861,920||861,920|
|**Total charitable expenditure**||878,798||878,798|
|**Total resources expended**||880,500||880,500|
|Net gains/(losses)oninvestments|**9**|-|20,226,663|20,226,663|
|**Net incoming resources before transfers**||2,647,225|20,226,663|22,873,888|
|Gross transfers between funds||{3,142,841)|
3,142,841||
|**Net movementinfunds**||(495,616)|23,369,504|22,873,888|
|Fund balances at 6 April 2020||1,823,565|75,389,547|77,213,112|
|**Fund balancesat5 April 2021**||1,327,949|98,759,051|100,087,000|
##
##
##
||||**2022**||**2021**|
|---|---|---|---|---|---|
||**Notes**|£|
£|£|
£|
|**Fixed assets**||||||
|Investments|**10**||103,522,250||98,759,051|
|**Current assets**||||||
|Debtors|**12**|387,856||373,590||
|Cash at bank and in hand||4,605,701||3,653,354||
|||4,993,557||4,026,944||
|**Creditors: amounts falling due within**||||||
|**one year**|**13**|(2,723,021)||(1,930,329)||
|Net current assets|||2,270,536||2,,096,615|
|**Total assets less current liabilities**|||105,792,786||100,,855,666|
|**Creditors: amounts falling due after**||||||
|**more than one year**|**14**||(331,367)||(768,666)|
|**Net assets**|||105,461,419||100,,087,000|
|**Capital funds**||||||
|General endownment funds|**16**||103,522,250||98,759,051|
|**Income funds**||||||
|Unrestricted funds|||1,939,169||1,327,949|
||||105,461,419||100,,087,000|
##
##
||||**2022**|**2021**||
|---|---|---|---|---|---|
||**Notes**|£|
£|£|£|
|**Cash flows from operating activities**||||||
|Cash absorbed by operations|**19**||(1,563,927)||(917,810)|
|**Investing activities**||||||
|Purchase of investments||(2,000,000)||(100,000)||
|Proceedsondisposalofinvestments||674,839||261,694||
|Investment income received||3,841,435||3,527,725||
|||||--||
|**Net cash generated from investing**||||||
|**activities**|||2,516,274||3,689,419|
|**Net cash used in financing activities**||||||
|**Net increaseincash and cash equivalents**|||952,347||2,771,609|
|Cash and cash equivalents at beginningofyear|||3,653,354||881,745|
|**Cash and cash equivalentsatendofyear**|||4,605,701||3,653,354|
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
||**Unrestricted**|Unrestricted|
|---|---|---|
||**funds**|funds|
||**2022**|2021|
||£|£|
|Interest received|5|296|
|Dividends and interest|3,841,430|3,527,429|
||3,841,435|3,527,725|
|||--|
##
||**Unrestricted**|Unrestricted|
|---|---|---|
||**funds**|funds|
||**2022**|2021|
||£|£|
|Portfolio management|2,149|1,702|
||2,149|1,702|
##
##
##
##
##
||**Grants**|Grants|
|---|---|---|
||**Awarded**|Awarded|
||**2022**|2021|
||£|£|
|Grants to institutions|1,880,504|861,920|
||1,880,504|861,920|
||**2022**|**2021**|
||£|£|
|DepartmentofBiochemistry - Specific RNAs||69,763|
|DepartmentofChemistry - Inorganic - Developing Biocatalysis||72,774|
|OUMNH a - Project IMAGOS||126,979|
|DepartmentofBiochemistry - Expanding Access||28,160|
|DepartmentofBiochemistry - Histone in genome stability||32,558|
|DepartmentofBiochemistry - Cryo-EM structure determination||50,184|
|DepartmentofBiochemistry - Purchase protein crystal imaging system||69,194|
|DCHI** - Focused ion beam and scanning electron microscope||366,495|
|DPAG - Support for year twoofa postdoc||39,906|
|DepartmentofBiochemistry - Defining the roleofPARPs in the DNA||32,252|
|DepartmentofPharmacology - Equipment request||11,238|
|KIR - Establishing Advanced Image Analysis|79,768||
|OBGA *** - Plant records management|61,561||
|DepartmentofBiochemistry - Support for outreach events|7,360||
|DepartmentofBiochemistry-Anultracentrifuge for Biochemistry|40,000||
|Royal Society - Human Genome Editing|140,000||
|DepartmentofBiochemistry - Support screening microscope|80,000||
|DPAG13-Advanced 3D Parkinson's stem cell disease models|143,697||
|DepartmentofBiochemistry - Phosphorylation sites|30,672||
|DepartmentofBiochemistry - Regulationofnon-coding RNAs|47,644||
|MSDO* - Bridging salary scheme|250,000||
##
##
|**6**|**Grants payable**||**(Continued)**|
|---|---|---|---|
||HistoryofScience Museum - Collecting COVID|251,989||
||EM Facility - Research assistant to support projects|152,260||
||DepartmentofBiochemistry - Target search mechanisms|5,890||
||DepartmentofBiochemistry - Modelling toolkit for glycans|45,076||
||DepartmentofBiochemistry - Genotoxic stress on epimutations|93,474||
||DepartmentofBiochemistry - Site-specific ADP-ribosylation|26,522||
||OUMNH a - Next generationofEPA Internships|112,969||
||DepartmentofBiochemistry - New suiteofelectron microscopes|500,000||
|||2,068,882|899,503|
||KIR Kennedy InstituteofRheumathology|||
||*Medical Sciences Division Oxford|||
||** Dorothy Crowfoot Hodgkin Institute|||
||*** Oxford Botanic Garden & Arboretum|||
||#DepartmentofPlant Sciences|||
||a Oxford University MuseumofNatural History|||
||~DepartmentofPhysiology, Anatomy and Genetics|||
||WIMM Weatherall InstituteofMolecular Medicine|||
|**Adjustments to grants duringtheyearwereasfollows:**|**2022**|**2021**|
|---|---|---|
||£|£|
|DepartmentofBiochemistry - Expanding user access to NMR - (30,306)||(30,306)|
|DepartmentofZoology - Support - (7, 168)||(7,168)|
|DepartmentofBiochemistry - Post doctoral support**(x2)**- (109)||(109)|
|DepartmentofBiochemistry - Nanobodies etc. facility (10) -|(10)||
|OUMNH a - Summer internship programme (26,556) -|(26,556)||
|Linacre College - Widening participation scholarships (1,052) -|(1,052)||
|Chemistry - Inorganic - Energized NanoconfinementofEnzymes (2,808) -|(2,808)||
|DepartmentofBiochemistry - Histone ADP-ribosylation (1) -|(1)||
|DepartmentofBiochemistry - Cryo-EM structure determination (13,926) -|(13,926)||
|DepartmentofBiochemistry - Defining the role PARPsinDNA Repair (327) -|(327)||
|DPAG~-Advanced3D Parkinson's stem cell disease models (143,697) -|(143,697)||
|DepartmentofBiochemistry-Target search mechanisms for bZIP (1) . - .|(1)||
||--||
||(188,378)|(37,583)|
||1,880,504|861,920|
##
##
##
##
##
|**2022**|**2021**|
|---|---|
|**Number**|**Number**|
##
|**Endowment**|Endowment|
|---|---|
|**funds**|funds|
|**general**|general|
|**2022**|2021|
|£|£|
|3,438,038|20,226,663|
##
||**Investments**|
|---|---|
||£|
|**Cost or valuation**||
|At 6 April 2021|98,759,051|
|Additions|2,000,000|
|Valuation changes|3,438,038|
|Disposals|(674,839)|
|At 5 April 2022|103,522,250|
|**Carrying amount**||
|At 05 April 2022|103,522,250|
|At 05 April 2021|98,759,051|
|**11**|**Financial instruments**|**2022**|**2021**|
|---|---|---|---|
|||£|£|
||**Carrying amountoffinancial assets**|||
||Instruments measured at fair value through profit or loss|103,522,250|98,759,051|
|**12**|**Debtors**|||
|||**2022**|**2021**|
||**Amounts falling due within one year:**|£|£|
||Other debtors|387,856|373,590|
##
##
##
|**13**|**Creditors: amounts falling due within one year**|||
|---|---|---|---|
|||**2022**|**2021**|
|||£|£|
||Grants payable|2,717,021|1,924,891|
||Accruals|6,000|5,438|
|||2,723,021|1,930,329|
|**14**|**Creditors: amounts falling due after more thanoneyear**|||
|||**2022**|**2021**|
|||£|£|
||Grants payable|331,367|768,666|
##
##
##
##
##
|**No**|**Grant**|**8/fwd2021**
**N**|**ew 2021/22 Ad**|**justments Pa**|**id 2020/21**
**C**|**/fwd 2022**|
|---|---|---|---|---|---|---|
|266|DepartmentofBiochemistry - Contribution to facility for nanobodies etc.|(50,000)|-|10|49,990||
|277|DepartmentofExperimental Psychology - retinal imaging for the eye|(30,000)|||30,000||
|279|DepartmentofBiochemistry - Confocal microscopy systems|(75,000)|-||75,000||
|**294**
298|OUMNH - Summer internship programme
DepartmentofChemistry - Chemical Biology Facility|(48,775)
(500,000)||26,556|500,000|(22,219)|
|CF 320
CF 332|King Edward School - Bursaries and refurbishment
OUM NH - public engagement with research - First Animals exhibition|(400,000)
(92,500)|-
-||100,000
92,500|(300,000)|
|CF 334
CF 335|DepartmentofPlant Sciences - Shaking incubator system
DepartmentofPlant Sciences - Field emission scanning electron scope|(16,919)
(159,166)|-||159,166|(16,919)|
|CF 336|**WIMM**- Establishing an imaging mass cyometry platform|(50,000)|||50,000||
|CF 338
CF341
CF 342|Linacre College - Widening participation scholarships
DepartmentofBiochemistry - Specific RNAs
DepartmentofChemistry - Inorganic - Developing biocatalysis|(386,175)
(69,763)
**(72,774)**||1,052
2,808|15,000
69,966|(370,123)
(69,763)|
|CF 343
CF 344
CF 345|OUMNH a - Project IMAGOS
DepartmentofBiochemistry - Expanding access
DepartmentofBiochemistry - Histoneingenome stability|(123,736)
(28,160)
(32,558)||1|40,962
32,557|(82,774)
(28,160)|
|CF 346|DepartmentofBiochemistry - Cryo-EM structure determination|(39,839)||3,581|36,258||
|CF 346e|DepartmentofBiochemistry - Cryo-EM structure determination|**(10,345)**||10,345|||
|CF 349|DepartmentofBiochemistry - Purchase protein crystal imaging system|(69,194)|||69,194||
|CF351
CF 352|DCHI** - Focused ion beam and scanning electron microscope
DPAG - Support for year twoofa postdoc|(366,495)
(39,906)||1|39,905|(366,495)|
|CF 354|DepartmentofBiochemistry - Defining the roleofPARPsinthe DNA|(32,252)||327|31,925||
|CF 356
CF 357
CF 358|KIR - Establishing Advanced Image Analysis
OBGA *** - Plant records management
DepartmentofBiochemistry - Support for outreach events||(79,768)
(61,561)
(7,360)||7,360|(79,768)
(61,561)|
|CF 359|DepartmentofBiochemistry-Anultracentrifuge for biochemistry||(40,000)||40,000||
|CF 360
CF361
CF 362|Royal Society - Human genome editing
DepartmentofBiochemistry - Support screening microscope
DPAGJ3-Advanced30Parkinson's stem cell disease models||(140,000)
(80,000)
(143,697)|1
143,697|79,999|(140,000)|
##
##
|**15**||**Reconciliationofmovement in grants during the year**|||||**(Continued)**|
|---|---|---|---|---|---|---|---|
|CF|363|DepartmentofBiochemistry - Phosphorylation sites||(30,672)|||(30,672)|
|CF|364|DepartmentofBiochemistry - Regulationofnon-coding RNAs||(47,644)|||(47,644)|
|CF|365|MSDO - Bridging salary scheme||(250,000)|||(250,000)|
|CF|366|HistoryofScience Museum - Collecting COVID||(251,989)|||(251,989)|
|CF|367|EM Facility - Research assistant to support projects||(152,260)|||(152,260)|
|CF|368|DepartmentofBiochemistry - Target search mechanisms for bZIP||(5,890)||5,889||
|CF|369|DepartmentofBiochemistry - Modelling toolkit for glycans||(45,076)|||(45,076)|
|CF|370|DepartmentofBiochemistry - Genotoxic stress on epimutations||(93,474)|||(93,474)|
|CF|371|DepartmentofBiochemistry - Site-specific ADP-ribosylation||(26,522)|||(26,522)|
|CF|372|OUMNH a - Next generationofEPA Internships||(112,969)|||(112,969)|
|CF|374|EM Facility - Newsuiteofelecton microscopes||(500,000)|||(500,000)|
||||(2,693,557)|(2,068,882)|188,380|1,525,671|(3,048,388)|
##
##
##
|**Balance at**|**Transfers**|**Revaluations**|**Balance at**|**Transfers**|**Revaluations**|**Balance at**|
|---|---|---|---|---|---|---|
|**6April 2020**||**gains and**|**6April2021**||**gains and**|**5April 2022**|
|||**losses**|||**losses**||
|£|£|£|£|£|£|£|
|75,389,547|3,142,841|20,226,663|98,759,051|1,325,161|3,438,038|103,522,250|
|75,389,547|3,142,841|20,226,663|98,759,051|1,325,161|3,438,038|103,522,250|
##
|**Analysisofnet assets b**|**etween funds**||||||
|---|---|---|---|---|---|---|
||**Unrestricted**|**Endowment**|**Total**|Unrestricted|Endowment|Total|
||**funds**|**funds**||funds|funds||
||**2022**|**2022**|**2022**|2021|2021|2021|
||£|£|£|£|£|£|
|Fund balances at 5|||||||
|April 2022 are|||||||
|representedby:|||||||
|Investments|-|103,522,250|103,522,250|-|98,759,051|98,,759,051|
|Current assets/(liabilities)|2,270,536||2,270,536|2,096,615||2,096,615|
|Long term liabilities|(331,367)||(331,367)|(768,666)||(768,666)|
||1,939,169|103,522,250|105,461,419|1,327,949|98,759,051|100,087,000|
##
|**19**|**Cash generated from operations**|**2022**|**2021**|
|---|---|---|---|
|||£|£|
||Surplus for the year|5,374,419|22,.873,888|
||Adjustments for:|||
||Investment income recognisedinstatementoffinancial activities|{3,841,435)|(3,527,725)|
||Gainondisposalofinvestments|(3,438,038)|(20,226,663)|
||Movements in working capital:|||
||(Increase)indebtors|(14,266)|(373,590)|
||Increaseincreditors|355,393|336,280|
|||--||
||**Cash absorbed by operations**|{1,563,927)|(917,810)|
##
##